Loading
A phase 1/2 trial of Pemetrexed, Carboplatin, Docetaxel in non-small-cell lung cancer and small-cell lung cancer, run by Dizal Pharmaceuticals, now recruiting.
DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7) is a phase 1/2 interventional study registered as NCT07070440 by Dizal Pharmaceuticals, with 180 participants planned, started 2025-07-16 and due to reach its primary completion in 2027-06. Interventions recorded: DZD6008, Pemetrexed, Carboplatin, Docetaxel. Conditions listed: Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Carboplatin, Small-cell lung cancer.
Shares Dizal Pharmaceutical, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Dizal Pharmaceutical, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Dizal Pharmaceutical, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer, Non-small-cell lung cancer.